Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004616 citationsEric Van Cutsem, Helgi van de Velde et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of H Neumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Neumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Neumann more than expected).
This network shows the impact of papers produced by H Neumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Neumann. The network helps show where H Neumann may publish in the future.
Co-authorship network of co-authors of H Neumann
This figure shows the co-authorship network connecting the top 25 collaborators of H Neumann.
A scholar is included among the top collaborators of H Neumann based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with H Neumann. H Neumann is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Cutsem, Eric Van, Helgi van de Velde, Petr Karásek, et al.. (2004). Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. Journal of Clinical Oncology. 22(8). 1430–1438.616 indexed citations breakdown →
4.
Vardi, Aliza, et al.. (1995). New considerations on the choice of irradiation dose rate in Citrus.2 indexed citations
Bleistein, N., H Neumann, Richard A. Handelsman, & L. P. Horwitz. (1977). Analysis of a nondegenerate decay system. Nuovo cimento della Società italiana di fisica. A, Nuclei, particles and fields. 41(3). 389–406.9 indexed citations
Mamoli, B. & H Neumann. (1975). [Electrophysiological studies on the prognosis in idiopathic facial paralysis].. PubMed. 54(12). 986–91.1 indexed citations
16.
Neumann, H, et al.. (1971). Auto-immunity and cutaneous porphyria.. PubMed. 199–201.4 indexed citations
17.
Immich, H, et al.. (1970). [Joint clinical study of a long term neuroleptic drug fluspirilene].. PubMed. 20(11). 1699–701.1 indexed citations
18.
Neumann, H, et al.. (1969). [The application of optical reader sheets in medical data recording using universal processing programs].. PubMed. 8(3). 141–7.1 indexed citations
Neumann, H, et al.. (1957). [Acalculia in a descriptive type of calculation].. PubMed. 28(3). 123–5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.